• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Ariel Linden, DRPH, president, Linden Consulting Group


Ariel Linden, DRPH, has contributed numerous peer-reviewed published articles, reflecting his knowledge in evaluating program effectiveness.

Ariel Linden, DrPH
President, Linden Consulting Group
Portland, Ore.

Dr. Linden's training as a health services researcher and his keen understanding of DM models have enabled him to evaluate the effectiveness of DM programs using robust research methods. He has provided DMAA-award winning academic support for use of event rate measurement, which results in much greater validity at much lower costs than actuarial measurement. His analytic techniques serve as models for evaluation of DM and wellness programs in both the United States and abroad.

Related Content
© 2024 MJH Life Sciences

All rights reserved.